Rigel Pharmaceuticals reported continued growth in net product sales driven by its targeted therapies addressing hematologic and oncologic rare diseases. The company’s commercial portfolio now includes three FDA-approved drugs—TAVALISSE, REZLIDHIA, and GAVRETO—with expanding market penetration in US hematology and oncology segments. Strategic collaborations enhance development efforts, notably for R289 in lower-risk myelodysplastic syndrome. While the biotech firm benefits from orphan drug exclusivity and a focused commercial footprint, it faces competitive pressures from larger pharma players, generic challenges, and evolving reimbursement landscapes. Rigel maintains a solid liquidity position with approximately $61 million in cash and manageable debt as of mid-2026.